Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind dose-finding study of VS411 in treatment-naive adults with chronic HIV-1 infection
2007-002460-98Phase 2Completed
- Sponsor
- ViroStatics
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VS411, hydroxyurea and didanosine in Human immunodeficiency virus infection type 1 (3 arms), sponsored by ViroStatics. Primary endpoints: Change from baseline in plasma HIV-1 RNA, Pharmacokinetics and pharmacodynamics of didanosine and hydroxyurea and 4 more. Started Feb 2008; status: completed.
02
Drugs
VS411hydroxyureadidanosine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-002460-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002460-98.